Literature DB >> 19152426

Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Christian Toso1, Sonal Asthana, David L Bigam, A M James Shapiro, Norman M Kneteman.   

Abstract

UNLABELLED: The current model of liver graft allocation in place in the United States favors transplantation of patients with small hepatocellular carcinomas (HCCs) within the Milan criteria (a single tumor up to 5 cm in diameter or up to three lesions, none larger than 3 cm). Although several reports have suggested that these criteria could be extended, there is currently no agreement on new selection tools. In this study, we performed an overview of 6478 adult recipients of an isolated first liver transplant registered in the Scientific Registry of Transplant Recipients (SRTR) database. From March 2002 to January 2008, increasing numbers of patients outside Milan criteria (P <or= 0.001) have been registered for a transplant, but they still represent less than 5% of the transplants performed for HCC. Of all the tested variables (tumor number, largest tumor size, and Milan and University of California San Francisco criteria), only total tumor volume (TTV; P <or= 0.05) and alpha fetoprotein (AFP; P <or= 0.001) could predict patient survival. While these two parameters demonstrated independent behaviors (no patient demonstrated an increase in both values), a composite score was defined, with patients with a TTV > 115 cm(3) or an AFP > 400 ng/mL being outside criteria. The combined TTV/AFP score efficiently predicted posttransplant survival (hazard ratio = 2, 95% confidence interval = 1.7-2.4, P <or= 0.001); patients not meeting these criteria had a survival below 50% at 3 years.
CONCLUSION: According to the present SRTR data, Milan criteria are too restrictive, and patients with larger TTV can enjoy satisfactory posttransplant survivals. A composite patient selection score combining TTV and AFP was the most effective of all tested staging criteria for the prediction of posttransplant patient survival for candidates with HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152426     DOI: 10.1002/hep.22693

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  93 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

Review 3.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

4.  Liver transplant for patients outside Milan criteria.

Authors:  Giovanni Battista Levi Sandri; Michel Rayar; Xingshun Qi; Pierleone Lucatelli
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-26

5.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

6.  "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

8.  Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Naoko Kamo; Toshimi Kaido; Shintaro Yagi; Hideaki Okajima; Shinji Uemoto
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

9.  Twenty years of Milan criteria: how far do we go.

Authors:  Po-Chih Yang; Nobuhisa Akamatsu; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 10.  Hepatocellular Cancer: Is Recurrence Inevitable?

Authors:  Levent Doganay
Journal:  J Gastrointest Cancer       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.